The purpose of this study was to investigate associations between the 14 reported loci (from a meta-analysis of genome-wide association studies [GWAS] in the Caucasian population) and vitiligo in the Chinese Han population.
Materials and Methods:
In this study 14 single nucleotide polymorphisms (SNPs) at 14 different genetic loci were evaluated for their association with viteligo in a Chinese Han cohort, including 1472 cases and 1472 controls of by using the Sequenom MassArray iPLEX1 system. A Bonferroni adjustment was used for multiple comparisons and pBonferroni <0.0056 was considered statistically significant.
Results:
The T allele of the locus within the FBXO45-NRROS gene (3q29) was significantly associated with vitiligo (odds ratio = 1.22, 95% confidence interval: 1.10-1.36, p = 0.0001). Association at the genotype level was strong (p = 0.0007). The other SNPs were not associated with vitiligo (pBonferroni >0.0056).
Conclusion:
A SNP at the rs6583331 locus 3q29 is associated with the susceptibility of vitiligo in the Chinese Han population, which suggests that there is a common genetic factor predisposing to the development of vitiligo in the Chinese and Caucasian populations.
Get full access to this article
View all access options for this article.
References
1.
AraseN, YangL, TanemuraA, et al. (2016) The effect of rhododendrol inhibition of NF-kappaB on melanocytes in the presence of tyrosinase. J Dermatol Sci, 83:157-159.
2.
BoniniMG, MalikAB. (2014) Regulating the regulator of ROS production. Cell Res, 24:908-909.
3.
CavalliG, HayashiM, JinY, et al. (2016) MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc Natl Acad Sci U S A, 113:1363-1368.
4.
ChenX, SahasrabuddheAA, SzankasiP, et al. (2014) Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival. Cell Death Differ, 21:1535-1545.
5.
DiazVM, de HerrerosAG (2016) F-box proteins: Keeping the epithelial-to-mesenchymal transition (EMT) in check. Semin Cancer Biol, 36:71-79.
6.
EzzedineK, LimHW, SuzukiT, et al. (2012) Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res, 25:E1-E13.
7.
FosterMW, ThompsonJW, ForresterMT, et al. (2013) Proteomic analysis of the NOS2 interactome in human airway epithelial cells. Nitric Oxide, 34:37-46.
8.
HayashiM, JinY, YorgovD, et al. (2016) Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. Proc Natl Acad Sci U S A, 113:1357-1362.
9.
HuDY, RenYQ, ZhuKJ, et al. (2011) Comparisons of clinical features of HLA-DRB1*07 positive and negative vitiligo patients in Chinese Han population. J Eur Acad Dermatol Venereol, 25:1299-1303.
10.
JinY, AndersenG, YorgovD, et al. (2016) Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat Genet, 48:1418-1424.
11.
JinY, BirleaSA, FainPR, et al. (2010a) Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med, 362:1686-1697.
12.
JinY, BirleaSA, FainPR, et al. (2010b) Common variants in FOXP1 are associated with generalized vitiligo. Nat Genet, 42:576-578.
13.
JinY, BirleaSA, FainPR, et al. (2011) Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol, 131:1308-1312.
14.
JinY, BirleaSA, FainPR, et al. (2012) Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet, 44:676-680.
15.
JinY, RobertsGHL, FerraraTM, et al. (2019) Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. Nat Commun, 10:391.
16.
LevandowskiCB, MaillouxCM, FerraraTM, et al. (2013) NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1beta processing via the NLRP1 inflammasome. Proc Natl Acad Sci U S A, 110:2952-2956.
LiuJ, ZhangZ, ChaiL, et al. (2013) Identification and characterization of a unique leucine-rich repeat protein (LRRC33) that inhibits Toll-like receptor-mediated NF-kappaB activation. Biochem Biophys Res Commun, 434:28-34.
19.
NoubadeR, WongK, OtaN, et al. (2014) NRROS negatively regulates reactive oxygen species during host defence and autoimmunity. Nature, 509:235-239.
20.
NunesDH, EsserLM. (2011) Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol, 86:241-248.
21.
PautzA, ArtJ, HahnS, et al. (2010) Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide, 23:75-93.
22.
PurcellS, NealeB, Todd-BrownK, et al. (2007) PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet, 81:559-575.
23.
QuanC, RenYQ, XiangLH, et al. (2010) Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet, 42:614-618.
24.
SpritzRA. (2012) Six decades of vitiligo genetics: Genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol, 132:268-273.
25.
SuX, MeiS, LiangX, et al. (2014) Epigenetically modulated LRRC33 acts as a negative physiological regulator for multiple Toll-like receptors. J Leukoc Biol, 96:17-26.
26.
TaiebA, PicardoM. (2007) The definition and assessment of vitiligo: A consensus report of the Vitiligo European Task Force. Pigment Cell Res, 20:27-35.
27.
TangXF, ZhangZ, HuDY, et al. (2013) Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J Invest Dermatol, 133:403-410.
28.
WangX, DuJ, WangT, et al. (2013) Prevalence and clinical profile of vitiligo in China: A community-based study in six cities. Acta Derm Venereol, 93:62-65.
29.
YoshidaK. (2005) Characterization of estrogen-induced F-box protein FBXO45. Oncol Rep, 14:531-535.
30.
ZhaoS, FangF, TangX, et al. (2017) An in-depth analysis identifies two new independent signals in 11q23.3 associated with vitiligo in the Chinese Han population. J Dermatol Sci, 88:103-109.
